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Mathematical models have provided important insights into acute viral
dynamics within individual patients. In this paper, we study the simplest
target cell-limitedmodels to investigate thewithin-host dynamics of influenza
A virus infection in humans. Despite the biological simplicity of the models,
we show how these can be used to understand the severity of the infection
and the key attributes of possible immunotherapy and antiviral drugs for
the treatment of infection at different times post infection. Through an analytic
approach, we derive and estimate simple summary biological quantities that
can provide novel insights into the infection dynamics and the definition of
clinical endpoints. We focus on nine quantities, including the area under the
viral load curve, peak viral load, the time to peak viral load and the level of
cell death due to infection. Using Markov chain Monte Carlo methods, we
fitted the models to data collected from 12 untreated volunteers who partici-
pated in two clinical studies that tested the antiviral drugs oseltamivir and
zanamivir. Based on the results, we also discuss various difficulties in deriving
precise estimates of the parameters, even in the very simple models con-
sidered, when experimental data are limited to viral load measures and/or
there is a limited number of viral load measurements post infection.1. Introduction
Influenza continues to be a significant cause of morbidity and mortality world-
wide [1]. Seasonal epidemics of influenza cause more than 300 000 deaths
annually around the world. In the USA alone, a typical seasonal influenza A
epidemic results in over 200 000 hospitalizations [2] and 36 000 deaths [3].
Influenza is a short-lived infection with an incubation period of approxi-
mately 2 days [4]. The standard pattern of virus kinetics is characterized by
rapid exponential growth, with a peak in viral load occurring 1–3 days post infec-
tion, followed by a decline over the subsequent 3–5 days. In patients with
immunodeficiency, the duration of infection may be prolonged [5,6].
Experimental studies on the typical course of influenza A in a patient have
provided useful insights into the processes controlling viral dynamics, especially
the associated immune response. Mathematical models have been used to
improve understanding of the infection dynamics. Influenza A virus kinetics in
the human body has been examined in a number of previous studies [7–10]. Var-
ious models that describe the infection dynamics in animals (for example in mice
[10–12] and horses [13,14]) have also facilitated the investigation of the immuno-
logical mechanisms involved in controlling influenza A replication. Models have
been developed to incorporate the innate immune response, the adaptive
response or both types of responses against influenza A [7–9,11–18]. Mathemat-
ical modelling has also helped in assessing the efficacy of influenza antiviral
treatments [19–22] such as neuraminidase inhibitors (oseltamivir and zanamivir)
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Figure 1. A schematic diagram of the TIV model (2.1)– (2.4) of viral
dynamics. (Online version in colour.)
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[17,25]. The models developed typically consist of systems of
ordinary differential equations (ODEs), based on the classic
viral dynamic model describing uninfected and infected cells
and free virus in the host [7,26–31]. Stochastic effects become
important when the viral load is at low levels [8] (for reviews
of the mathematical model development, see [32–34]).
Despite the availability of a range of mathematical and
statistical tools, limitations in data availability and measure-
ment issues in clinical studies of infected patients hinder
the development of complex models that will accurately pre-
dict the infection dynamics and provide insight into the exact
mechanisms responsible for its control. In this paper, we con-
sider the simplest within-host models of viral dynamics.
We assess the validity of these models by fitting to data
collected from 12 untreated volunteers experimentally inocu-
lated with human influenza A, but left untreated by drugs
or immunotherapeutic agents. Despite the biological sim-
plicity of these models, they can facilitate the assessment
of infection-related morbidity and the efficacies of immuno-
therapies or antiviral treatments and help in the design of
control and prevention strategies. We derive and estimate
simple quantities that reflect the severity of the infection at
different times post acquisition and can be considered as
potential endpoints in clinical trials. Such quantities include
the area under the viral load curve, the peak viral load, the
time to peak viral load and the level of cell death due to infec-
tion. The analytical results derived shed light on important
parameters that influence patterns in within-patient viral kin-
etics. Based on the results, we also discuss problems arising
in predicting the viral dynamics and evaluating therapeutic
interventions when the quality of clinical data on viral load
is suboptimal. We provide guidance on what to measure,
and when and how frequently, in order to accurately describe
the infection dynamics and facilitate the accurate assessment
of therapies that restrict viral growth.2. Material and methods
2.1. Simple mathematical models of viral dynamics
The main effects of the immune response on viral populations
can be simply classified as one of the following: (i) decreasing
the infection of susceptible cells, (ii) reducing the production of
virus by infected cells, (iii) killing infected cells, and (iv) increas-
ing the clearance rate of free virus particles. The simplest model
of influenza A virus infection that incorporates implicitly or
explicitly these four mechanisms is the TIV model [7]. This
model assumes that susceptible cells (primarily epithelial cells),
T, become infected when in contact with free infectious virus par-
ticles, V, via a mass-action process with rate b. Virus is produced
in direct proportion to the number of (productively) infected
cells I at rate p per infected cell and is lost at rate c per virion due
to non-specific mechanisms that include immune response and
natural virus decomposition. An infected cell dies or is killed by
immune cells and other non-specific mechanisms with rate dI.
Hence, infected cells produce an average p/dI virions during
their lifetime. The ODEs that describe this dynamical system are
as follows:
dT
dt
¼ bVT, ð2:1Þ
dI
dt
¼ bVT –dI I ð2:2Þand
dV
dt
¼ pI  cV, ð2:3Þ
with initial conditions
Tð0Þ ¼ T0, Ið0Þ ¼ I0, Vð0Þ ¼ V0: ð2:4Þ
The TIV model, (2.1)–(2.4), is shown schematically (figure 1).
Owing to the paucity of quantitative information on the
clearance rate of the virus and the death rate of infected cells,
we focus on a simpler version of the TIV model which assumes
that the viral dynamics is much faster than the infected cell
dynamics and that a quasi-stationary state at which V ¼ pI/c is
attained very quickly [35–37]. In this case, the TIV model is
reduced to the following pair of equations:
dT
dt
¼ bVT ð2:5Þ
and
dV
dt
¼ rbVT  gV, ð2:6Þ
with initial conditions
Tð0Þ ¼ T0, Vð0Þ ¼ V0: ð2:7Þ
The parameter g is the death rate of infected cells dI in the TIV
model and r can be interpreted as p/c. However, as the par-
ameters p and c cannot be estimated independently, we will
consider r as a single parameter. Model (2.5)–(2.7) will be
referred to as the TV model. The TV model has the same struc-
ture as the susceptible–infectious–recovered (SIR) model in
infectious disease epidemiology of viral spread in a population
of hosts [38–40] and thus most of the results derived for the
SIR model in host populations can be applied in the context of
within-host viral dynamics.
The TV model can be extended to the so-called TVA model to
include a representation of the overall action strength of the
immune response against influenzaA (see electronic supplementary
material, S1). All three models, TIV, TV and TVA, predict changes in
viral load over time post infection accurately. However, the TV and
TVAmodels are ‘better’ models; the fit of the TIVmodel to observed
viral loaddata is almost equivalent to that of the TVandTVAmodels
(data are not shown) and there are no data to support the estimation
of the extra parameters in the more complex model. As there is no
independent information about the dynamics of infected cells, the
quasi-stationarystate assumption in the TVandTVAmodels is there-
fore reasonable. We focus on the TV model, but in the electronic
supplementarymaterial, S3,we add to previous published analytical
results for the TIV model and in the electronic supplementary
material, S1, we discuss the TVAmodel in more detail.
Table 1 summarizes the variables and parameters of all the
models considered in this paper.
The abovemodels encapsulate a number of biological assump-
tions. For example, the regeneration and natural death of target
Table 1. Notation of the models’ variables and parameters.
notation meaning units
model variables
T cells susceptible to infection cell
I infected cells cell
V viral load TCID50 ml
21
A immune response
model parameters
b infection rate (TCID50/ml)
21  day21
p viral production rate
per infected cell
TCID50 ml
21  day21
c viral clearance rate day21
dI death rate of an
infected cell
day21
g viral decay rate day21
r rate at which target cells
that become infected
produce virus in the TV
and TVA models
TCID50 ml
21
w clearance rate of virus by
immune response
day21
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cesses compared with the time scale of influenza infection [41,42].
Therefore, even in cases of severe infection the viruswill eventually
decline due to the depletion of susceptible target cells. Including
the regeneration of target cells does not improve the model fit in
most cases [7,10–14,25,43]. An additional assumption is that
there is no delay between cell infection and production of virus
(a latent phase). Moreover, it should be noted that if no death of
infected cells occurs during the latent phase, then the delay
simply postpones the infection dynamics (delays the onset of the
infection, reduces the peak of the viral load and increases the dur-
ation of the infection) without reducing the amount of viral
shedding significantly (if regrowth of susceptible cells is con-
sidered then increasing the delay of virus production will result
in a reduction in the amount of viral shedding). Finally, the loss
of virions through cell entry is also considered negligible and
absorbed into the loss term 2cV, given that any one cell has the
potential to produce between 103 and 104 virions [44], which is
much more than the number of virions needed to infect a cell
[45]. This loss might be important in in vitro models [25].
2.2. Parameter estimation
2.2.1. Datasets used
We use viral load data from two different datasets: the first consists
of six volunteers from the placebo group of the oseltamivir trial
conducted by Roche [46]. All the participants were healthy adults
andscreened forhaemagglutination inhibition titre. Intranasal inocu-
lationwith 106 (50% tissue culture) of a safety-tested pool (TCID50) of
human A/Texas/36/91 H1N1 influenza virus was performed on
day 0.Nasal lavage fluidswere collected for virus isolation and titra-
tion by standard methods on days 2–8. The second dataset also
consists of six volunteers who were part of the placebo group of
thezanamivir trial conductedbyGlaxoSmithKline (GSK).Thevolun-
teers in this trial were also inoculated with human H1N1 influenza
virus (A/Texas/91 H1N1) following a similar procedure.For themodel fitting and the estimationof theparameters,when
two ormore (sequential) viral load data points fall below the detec-
tion limit we exclude them all but the first one. In this case, the first
undetectable viral loaddatapoint is set to beequal to thevalueof the
detection limit. In the data analysed in this study, the value of
the detection limit was not known and it was set to be equal to 0.7
TCID50 ml
21, which is 0.05 TCID50 ml
21 below the smallest
measurement value in the two datasets considered.
2.2.2. Fitting procedure
In the TV model the parameters r, I0 and T0 cannot be estimated
independently. We fixed T0 at 4  108 cells [7] and I0 at 0. A struc-
tural identifiability analysis of the TV model [47] shows that the
estimation of the identifiable parameters (b, g, r or T0) requires at
least five measurements of viral load at distinct time points. How-
ever, examining the pairwise relationships between the parameters
(see §3.2), it is observed that all the parameters are correlated and it
is thus not possible to produce good estimates of each individually.
Owing to the correlation between b and r, we reparametrized the
model by replacing rb in equation (2.6) by l andwe estimated l and
b (note: b and l are also correlated).
We fitted the TV model to data and estimated the parameters
for each patient independently using a random-walk Metropolis–
Hastings algorithm. Independent prior distributions were chosen
for each of the unknown parameters V0, b, l and g. An exponential
distribution with mean 100 was chosen for V0 and g. A uniform
distribution [0–0.003] (except for patients 3 and 4 in the Roche
-dataset, [0–0.01]) was chosen for b while a uniform distribution
[0–0.0000001] was chosen for l. It was assumed that the measured
viral loadswere lognormally distributed around the true viral loads
[48] with standard deviation 0.3 log10 (this was based on data
provided in [49], but preliminary studies show that the assumed
standard deviation of the lognormal distribution does not signifi-
cantly affect the parameter estimates). For each individual
dataset, 8.1  105 sampling iterations were performed, of which
the first 104 iterations were discarded. To reduce autocorrelation,
every 500th sample was recorded [50]. Convergence was assessed
visually from the traces of each parameter.
2.3. Infection-related quantities
We derive either exact or approximate solutions of nine infection-
related quantities that can help us to interpret the viral load scores
in termsof infection severityatboth the individual and thepopulation
level. The quantities considered are the following: the basic reproduc-
tion ratio R0 and the viral growth rate r0, which indicate the speed at
which the virusdisseminateswithin the humanhost at the early stage
of infection; the generation time Tg [51], which indicates the speed at
which the infection spreads in thepopulation; the area under the viral
load curveAV [9,33],which indicates the infectiousness of thehost; the
peak viral load PV [33], which is thought to be correlated with symp-
tomscores; the time topeakviral load tVpeak [10,17],which canbeused
forassessing infectionprogression; the viral decay rate rd,which is the
rateofviral clearanceat the late stageof infection; thedurationof infec-
tion td [33], which shows the time scale of the infection and can
indicate the time in which the patient is infectious; and the fraction
of dead cells at the end of the infection D [10,33], which indicates
the damage to the tissue caused by the infection, the occurrence of
some respiratory symptoms and the time to recovery. The quantities
are summarized in the schematic in figure 2. For more information
about these quantities and the importance of each of them, see
electronic supplementary material, S2.3. Results
The TV model fits to the placebo data and the uncertainty
in the model solution is illustrated in figure 3. Despite the
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Figure 2. Summary of the infection-related quantities: the basic reproduction ratio, the initial viral growth rate, the generation time, the peak viral load, the time to
peak viral load, the infection duration (time interval in which the viral load is above a threshold), the area under the viral load curve above a threshold and the
fraction of dead cells. (Online version in colour.)
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Figure 3. TV model fit: the black line represents the median estimate of viral dynamics (in log10 scale) and yellow lines are viral dynamic curves based on 10 000
samples from the posterior distribution of the parameters. Red squares are viral load data points. (a) Placebo-group patients from the oseltamivir trial (Roche
dataset); (b) placebo-group patients from the zanamivir trial (GSK dataset).
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model provides a good description of the data for most of
the subjects.
3.1. Infection-related quantities
In table 2, we summarize how the infection-related quantities
in the TV model are affected by the administration of treat-
ments that decrease the rate of infection (e.g. adamantane
antiviral drugs [17,25]) and the viral production rate
(e.g. neuraminidase inhibitors [7,8,17,23]) and hypothetical
treatments that increase the virus clearance rate (e.g. mono-
clonal antibodies [52]). We also present the influence of the
initial viral load. The results presented are for cases where
the basic reproduction ratio R0 is greater than 1. A generalconclusion is that the time of treatment during the infection
is very important and, based on the models considered, its
effect is highly dependent on the number of the remaining sus-
ceptible cells at this time. In table 3, we summarize the main
determinants of some of the infection-related quantities as
defined by the mathematical expressions derived. In table 4,
we show the estimates of the infection-related quantities in
the TV model based on the parameter estimates presented
in the electronic supplementary material, table S5. We present
both the numerical and analytical solution showing the good
accuracy of the analytical results based on novel approxi-
mations. Figures 4 and 5 illustrate, respectively, the
variability of the parameter estimates and the variability of
the infection-related quantities between patients.
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Table 3. Summary of the main parameters determining the infection-related quantities as derived from analytical results.
infection-related
quantities
area under the
viral load curve
fraction of
dead cells
time to peak
viral load peak viral load viral decay rate
mainly inﬂuenced
by
R0 R0 all parameters,
including V0
viral production
rate (TV model)
death rate of infected
cells, virus
clearance rate
rsif.royalsocietypublishing.org
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In the TV model, the basic reproduction ratio is given by
R0ðTVÞ ¼ rbT0=g. In our study, thewithin-host R0 has been esti-
mated to be approximately 3.5 (table 4).R0 is highly dependent
on the model choice and the assumptions about the immune
responses following infection. Moderate to high values of R0
are expected in influenza A as the virus disseminates very
rapidly within the host.
3.1.2. Viral growth rate, r0
Assuming that at the initial stage of the infection the number
of target cells remains constant, it can be shown that the
initial viral growth rate in the TV model can be described
very well by rbT0 2 g. The rate at which the virus population
grows in the patient over the initial period of infection is
essentially independent of V0. Typically, the viral growth
rate of influenza A is high, suggesting a high value of R0
[7]. In our study, the average r0 has been calculated to be
approximately equal to 7.8 day21 (table 4).
3.1.3. Generation time, Tg
An approximate solution for the average generation time (at the
population level) during the course of the infection for the TIV
and TV models is derived in the electronic supplementary
material, S3F. Increasing the infection rate, the viral production
rate, the initial number of target cells or the initial viral load
yields lower Tg values. When R0 is relatively large, the increase
in the viral clearance rate and the death rate of infected cells also
results in lower values forTg.Moreover, asR0 decreases and the
number of cells that become infected decreases, the increase in
these two rates yields higher Tg values. The TV model predicts
an average generation time of influenzaA infection at the popu-
lation level of around 2.6 days (table 4). This agrees with
previous estimations using different datasets [9,53].
3.1.4. Area under the viral load curve, AV
In the electronic supplementary material, S3A, a formula for
the area under the viral load curve, AV, in the target cell-lim-
ited models TIV and TV is derived. From the approximation
derived, it is clear that the basic reproduction ratio is the main
determinant of the value of AV. In the TV model, as b
increases AV increases exponentially and converges to (V0 þ
rT0)/g, which corresponds to the maximum AV (further
increase is not possible due to the depletion of susceptible
cells). AV increases almost linearly with the viral production
rate (especially when the parameter values are such that all
susceptible cells eventually get infected) and T0, and it has
an inverse relationship with the viral clearance rate and the
death rate of infected cells. AV is not affected much by vary-
ing V0 as long as V0 remains low (as will normally be the case
in practice).3.1.5. Peak viral load, PV
An exact formula of the peak viral load in the TV model,
PV(TV), is derived in the electronic supplementary material,
S3C (an approximation of PV(TIV) is also derived in the elec-
tronic supplementary material, S3C). From the solution of
PV(TV), it can be observed that, although the peak viral load
is affected by all model parameters, its value is mainly
influenced by the viral production rate r.
As the infection rate b increases, PV increases and con-
verges to a constant, which corresponds to the maximum
viral load when all the cells are already infected before the
start of the decay phase. If PV reaches this value, then any
antiviral treatment for the protection of susceptible cells
that is administered after the time of the peak will have
very little or no effect during the viral decay period. By con-
trast, PV increases linearly with the viral production rate
and T0. Hence, an infection by a viral strain with a high
replication rate might be more severe than an infection
with a higher cell infection rate (see also [12]). Therefore,
depending on the other parameter values, therapeutic
interventions to reduce viral replication will be more effec-
tive than those that reduce viral cell infectivity. Similarly,
therapeutic, or prophylactic, interventions that aim at the
limitation of target cells, e.g. by inducing resistance to
virus, may be more effective. PV has an inverse relationship
with the viral clearance rate (and the death rate of infected
cells in the TIV model, with the increase of the first being
slightly more important than that of the second). There is
almost no variation of PV with V0.3.1.6. Time to peak viral load, tVpeak
An approximation of the time to the peak of viral load for the
TIV and TV models is given in the electronic supplementary
material, S3D. tVpeak decreases as the infection rate, the viral
production rate and the initial number of susceptible cells
increase. In cases where the virus disseminates quickly and
infects the majority of susceptible cells, a decrease of tVpeak is
also observed with increasing viral clearance and infected
cell death rates. Otherwise, after a certain value, an increase
in these rates delays the onset of the infection and therefore
the time to peak. The decrease of V0 also yields higher
tVpeak . An infection where the peak viral load occurs either
much earlier or later is not necessarily a more severe infection
and needs to be considered with other measures of infection
severity such as the peak viral load and the area under the
viral load curve. For example, in table 2 it can be observed
that the late occurrence of the peak viral load does not
imply a severe infection with respect to the value of the
peak. In the standard influenza A virus kinetic pattern,
viral load reaches its maximum level approximately 2 days
after the initiation of the infection [53], which is in good
agreement with our model prediction (table 4).
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Figure 4. Estimated posterior medians of individual parameters and the corresponding 95% credible intervals for the 12 patients in the two datasets. The estimated
values of the individual parameters are presented in the electronic supplementary material, table S5.
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Figure 5. Scatter plots illustrating the variability of the infection-related quantities between the 12 patients in the two datasets. Each colour represents a patient.
Numerical solutions are represented by filled circles and analytical solutions by asterisks. The estimated values of the quantities are presented in table 4.
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A derivation of an approximate solution of the viral load
during the decay phase for the TIV model is shown in [14]
(see also [54]). In the TV model, after the infection of all
target cells, the viral load decreases exponentially at rate g (in
the late decay phase the main or the only process that takes
place is the clearance of the virus). This clearance rate is a com-
posite of the natural death rates of infected cells and free virus
and the action of the immune system in enhancing the clear-
ance of both. Although all model parameters can affect the
early phase of virus growth, the decay of the virus at
the later stage of the infection depends almost exclusively
on the death rate of infected cells and the virus clearance rate
(in the TIV model, the parameter that has the lower value
dominates towards the end of the infection [14,54]). This
dependence suggests that a treatment acting on the infection
rate and/or the viral production rate will only be effective if
it is administered at the early stage of the infection. A treatment
administered after the peak viral loadwill bemost effective if itacts on the death rate of infected cells and/or the viral clearance
rate. The average viral decay rate in this studywas calculated to
be approximately 4.4 day21 (table 4).3.1.8. Duration of infection, td
An approximate solution of the duration of infection in the TV
model is derived in the electronic supplementarymaterial, S3E.
Increasing the infection rate and the number of target cells
results in the increase of the basic reproduction ratio and the
rapid dissemination of the virus. The rapid infection of the
target cells results in the fast convergence to the infection-free
steady state where viral load falls to zero. When the infection
rate gets too large, a further increase has no significant effect
on the infection duration, which then corresponds to the mini-
mum time needed for the infection of all susceptible cells, their
death and the clearance of the virus. A similar situation is
observed when the initial number of target cells gets very
large. An increase in the viral production rate also decreases
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duction is very large, further increase yields higher durations
of infection, as then all (or almost all) cells get infected quickly.
In this case, the increase in the rate at which free virus is pro-
duced by each infected cell results in increased time needed
for virus clearance. For relatively large values of R0, the infec-
tion duration also decreases as the viral clearance rate and
the death rate of infected cells increase. After a certain value
and as R0 decreases, the virus disseminates at lower rates
and, although a significant decrease in peak viral load and
the number of dead cells is observed, the time needed for the
virus to be cleared increases due to the high availability of
susceptible cells. Therefore, based on the simple models con-
sidered, a long infection is not necessarily a severe infection.
The observed increase in the infection duration with the
decrease of the basic reproduction ratio is counter-intuitive,
as an infection with low rates of transmissibility between
cells should last for less time. This might be considered a limit-
ation of models without an explicit description of immune
responses. The TV model predicts that the infection duration
is about 5.8 days (table 4), which is approximately the infec-
tious period of a typical influenza A infection recorded in
clinical studieswhere the date of infection is known (household
transmission studies [55]).
3.1.9. Fraction of dead cells at the end of the infection, D
In the electronic supplementary material, S3B, we derive an
approximate solution of D for both the TIV and TV models.
The solutions of D also show that R0 is the main determinant
of the fraction of dead cells at the end of the infection. In par-
ticular, decreasing the infection rate, the viral production
rate, the initial number of target cells or the initial viral load
decreases the total level of cell death due to infection.
A decrease in the number of dead cells can also be achieved
by increasing the viral clearance rate and the death rate of
infected cells. It can be concluded that, although infections
with lower infection and virus production rate can be less
severe with respect to the peak viral load and the damage
they cause to the tissue, they can last longer. The models con-
sidered in this paper predict that the majority of epithelial
cells will die due to infection (table 4).
3.2. Problems in the parameter estimation due to
limitations in data availability
Clinical data availability limits the development and validation
of more complex models of acute viral infections that can
describe the immunologicalmechanisms and cellular dynamics
in more detail. The question therefore arises of whether the
quality and quantity of available viral load data are sufficient
to support even the simplest models developed to predict
viral dynamics and the impact of therapeutic interventions.
3.2.1. Quantity of viral load measurements
For the simplest within-host viral dynamics mathematical
model (2.5)–(2.7), at least five viral load measurements at dis-
tinct time points (ideally at least one in each day) are required
to estimate the unknown model parameters [47]. In this
study, 174 out of 191 individual patients were excluded
from the analysis because of either the limited number of
viral load measurements made in the clinical observation
periods post infection or the large number of missing datapoints (for example, the data points during the initial phase
of the infection). The maximum number of viral load
measurements in one patient was eight in 7 days of infection,
which is sufficient for making predictions but not entirely
adequate for deriving precise parameter estimates and esti-
mates of the infection-related quantities. As illustrated in
figure 3, more measurements should be taken during the
nonlinear phase, around the peak viral load, where in most
cases high uncertainty occurs. Two (precise) viral load
measurements at distinct time points in each of the initial
viral growth and late viral decay phases might be enough
to accurately approximate the rates of increase and decrease
of the viral load curve. However, although the durations of
these phases have been estimated [54], these vary between
patients, even within the fairly homogeneous sample of
patients with respect to age used in parameter estimation
(table 4 and figure 5).
3.2.2. Precision of viral load measurements
In no dataset was there information about the error in the
sampling and measurement methods. Consequently, this
introduces a degree of uncertainty regardless of the model
accuracy to describe given data (and, thus, more frequent
measurements alone will not necessarily reduce the uncer-
tainty in the model predictions, figure 3). Ideally, replicating
both the viral load assays and sampling at one time point
from the same patient would enable us to estimate the error
in the measurement of viral load and improve the model pre-
dictions. Hence, given that we take the minimum number of
measurements required to estimate the parameters (five in
the TV model), it might be better to acquire replicate measure-
ments and get more precise values of the viral load instead of
taking samples more frequently at different time points. Ide-
ally, both should be done in clinical epidemiological studies
of acute infections. However, we acknowledge that, apart
from the practical issues in taking multiple samples from the
patients in time points close to each other, other sources of
variance might affect the accuracy of the measured viral load.
For example, the virus shed by patients may differ at different
times of the day.
Note that, in the absence of independent information
about parameter values, more precise viral load measure-
ments alone will not necessarily reduce the uncertainty of
parameter estimates due to the correlations between them
(see §3.2.3).
3.2.3. Availability of data other than viral load
Although the model describes the viral load data well, the
absence of information about the values of key biological par-
ameters and the dynamics of uninfected and infected cells
makes parameter estimation difficult. The high correlation
between themodel parameters results in equivalent predictions
of the model for a wide parameter space. The individual pos-
terior medians and the corresponding 95% credible intervals
for the four unknown parameters of the TVmodel are summar-
ized in the electronic supplementary material, table S5. In the
electronic supplementary material, figure S4.2, we provide
plots of the posterior distributions of each of these parameters.
The correlations between the parameters for each patient
are illustrated by pairwise scatter plots of the parameters (elec-
tronic supplementary material, figures S4.3–S4.8). There is
correlation between almost all parameters. In particular, in
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lated with parameter b and changes linearly with parameter
l, while l is inversely proportional to b. Although the relation-
ships of b, g and l with the initial viral load V0 are not clear,
it seems thatV0 is inversely proportional to b and l and not par-
ticularly related to g. Moreover, variation in V0 does not
influence the model fit much, unless V0 varies from very
small to very large values. The correlations between the
model parameters are not surprising as virus infects cells and
in turn infected cells produce more virus. Therefore, the virus
dynamics can be controlled by just protecting the cells not yet
infected, which can be achieved either by decreasing the infec-
tion rate or the rate at which virus is produced by each infected
cell or by increasing either the killing rate of infected cells or the
clearance rate of the virus. Independentmeasurements of some
unknown model parameters would therefore help to produce
more precise estimates of the remaining parameters.
Despite the high uncertainty in the estimates of the values
of single parameters, their productmay be estimatedmore pre-
cisely, resulting in the derivation of more accurate estimates of
some of the infection-related quantities. For example, figure
S4.1 in the electronic supplementary material S4 illustrates
that the basic reproduction ratio R0 can be estimated precisely
irrespective of the high uncertainty in individual parameter
estimates (R0 ¼ lT0/g is eventually equal to the slope of
the line showing the linear relationship between l and g, illus-
trated in the electronic supplementary material, figure S4.7,
multiplied by the initial number of target cells T0).
3.2.4. Unknown lower limit of quantification
The different viral load assays differ in the reported lower
limits of quantitation (LLOQ) and detection. In our analysis,
we had no information on the LLOQ and set it to 0.7
TCID50 ml
21. However, the choice of this value might signifi-
cantly influence both the model fit and the uncertainty in the
parameter estimates.
3.2.5. Unknown sampling time
During our study, the exact sampling time during a day in the
data we used was unknown. Given the available information,
we assumed that in the Roche dataset samples were taken
every 0.5 days between days 1 and 3 and every 1 day after-
wards. In the GSK dataset, we assumed that samples were
taken exactly every 24 h. However, the precise sampling times
can significantly affect the model predictions and therefore
they should be recorded. Recording whether the sample was
taken in the morning or afternoon is not enough, as variations
in the sampling time by some hours might be influential.4. Discussion
In the past few decades, mathematical model development
and its use in the study of infectious diseases in general,
and influenza A in particular, has largely focused on disease
spread and control within populations of hosts [56]. Models
of viral dynamics within an individual person serve many
purposes, including creating a better understanding of what
determines the temporal trajectory of viral load over time,
identifying what needs to be measured experimentally and
facilitating the choice of endpoints in clinical trials of possible
therapies. Precise mathematical description of viral dynamics
also facilitates understanding of the immune response andthe assessment of the efficacy of antiviral treatments. It also
plays an indirect role in understanding virus transmission
between hosts, due to the relationship between viral load
and infectiousness, and it can help in the evaluation of thera-
peutic treatments as part of the development of effective
strategies for the mitigation and control of epidemics.
Mathematical models with varying complexity have
been developed and analysed by analytical and numeri-
cal approaches to provide a description of the growth and
decay of the influenza A virus within the patient. However,
gaps in knowledge, especially concerning the role of different
immune system components and the lack of detailed biologi-
cal data on, for example, the life expectancies of cells and free
virus at different stages of infection, limit model validation.
In this paper, we revisited and extended simple classic
models of viral kinetics to study the influenza A infection
within the human body. Despite their simplicity, models that
exclude the explicit representation of the immune responses
can adequately explain observed patterns of viral growth and
decay in patients and facilitate an understanding of the pro-
cesses that have the greatest impact on the course of
infection. One of the advantages of using simple models to
describe the infection dynamics is that a number of quantities
that reflect the severity of the infection, and some of them
can be considered as clinical endpoints used in the assessment
of treatments, can be derived analytically. Owing to the varia-
bility of the measurements of viral load, and clinical outcome,
as well as the limited number of measurements, the derivation
of reliable estimates of such quantities directly from the raw
data would be difficult. We derived approximate expressions
and estimations of a series of morbidity and viral growth and
decay related measures, such as the area under the viral load
curve, the duration of infection, time to peak viral load and
the slope of the viral decay curve, and focused on identifying
their key determinants. New results are presented on some of
these measures. This focus is a first step in developing tools
to aid in the design of clinical trials of candidate therapies to
treat infected patients or susceptible individuals to lessen the
impact of infection. Despite the limited information that each
of these quantities can provide independently, and difficulties
in measuring them, the assessment of all quantities together
provides insights into how different interventions will act on
the observed course of infection when applied at different
times post infection and post the initiation of treatment. Most
importantly, they also help define what to measure in clinical
trials of therapies.
Although we focused on influenza A virus infection, the
models and results are applicable to other acute viral infections
where measurable viral load persists for a few days to a few
weeks in the patient. The fast dynamics of such infections
and the short duration of viral replication create problems in
the design and conducting of quantitative clinical studies of
possible therapies involving sampling from infected patients.
However, problems in the estimation of the model parameters
and the accurate prediction of the viral load dynamics can be
resolved by improving data quality. Based on our analysis,
we suggest that frequent sampling at defined time points is
essential to creating a deeper understanding of viral kinetics
and between-patient variation. More frequent viral load
measurements will be more useful if they are accompanied by
measurement error data. Reduction of the measurement error
of viral load could be achieved by running replicate measure-
ments and replicating sampling of the same patient at one
rsif.royalsocietypublishing.org
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very important in using these models to guide the design of
clinical trials of therapeutic interventions. Determining the
importance of variance in viral load between patients and
during therapy requires understanding the variation inherent
in the sampling and measurements methods. Describing
these two sources of variation (between patients and within
the sampling and measurement method) is essential in the
determination of the efficacy of a therapeutic intervention.
Improving the precision of viral load measurements alone
will not necessarily result in more accurate parameter estimates.
Amajor need in future clinical, animalmodel and in vitro studies
is the determination of basic population dynamic parameters,
such as cell life expectancies with and without infection and
the virus clearance rate. At present their accurate estimation
fromthe time courseof infection in thepatient is fraughtwithdif-
ficulty, due to the correlations between them, and independent
measurements of at least some of them is required.
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